3 citations
,
September 2020 in “Bladder cancer” In this study, 5α-reductase inhibitors were found to have no significant impact on preventing tumorigenesis or progression in in vitro models of urothelial cancer.
3 citations
,
July 2014 in “Indian Journal of Surgery” Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.
9 citations
,
August 2019 in “Clinical genitourinary cancer” This study suggests that 5-alpha reductase inhibitors may reduce invasive cancer features and improve survival in men undergoing radical cystectomy for high-grade urothelial carcinoma, although further research is needed to confirm these findings.
23 citations
,
September 2020 in “BMC Cancer” This retrospective cohort study found that patients using 5α-reductase inhibitors had reduced bladder cancer-related mortality compared to nonusers, with no significant effect on bladder cancer recurrence or upper tract urothelial carcinoma mortality.
4 citations
,
December 2019 in “Minerva Urology and Nephrology” This study found that patients with non-muscle invasive bladder cancer who were treated with 5-alpha reductase inhibitors had lower recurrence rates and higher recurrence-free survival rates compared to untreated patients.
